Korro Bio logo

Korro BioNASDAQ: KRRO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 October 2019

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$540.82 M
-26%vs. 3y high
66%vs. sector
-vs. 3y high
-vs. sector
-43%vs. 3y high
67%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 20:49:15 GMT
$58.16+$0.66(+1.15%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

KRRO Latest News

Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet
zacks.com16 October 2024 Sentiment: POSITIVE

The consensus price target hints at a 239.5% upside potential for Korro Bio, Inc. (KRRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
globenewswire.com30 September 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024.

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
globenewswire.com13 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2024 and provided an update on its recent progress and anticipated milestones.

Korro to Participate in Upcoming June Investor and Scientific Conferences
globenewswire.com30 May 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
globenewswire.com20 May 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) --  Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD.

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
Seeking Alpha14 March 2024 Sentiment: POSITIVE

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.

Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade
Zacks Investment Research27 February 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 86.9% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?
Zacks Investment Research09 February 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What type of business is Korro Bio?

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

What sector is Korro Bio in?

Korro Bio is in the Healthcare sector

What industry is Korro Bio in?

Korro Bio is in the Biotechnology industry

What country is Korro Bio from?

Korro Bio is headquartered in United States

When did Korro Bio go public?

Korro Bio initial public offering (IPO) was on 03 October 2019

What is Korro Bio website?

https://www.korrobio.com

Is Korro Bio in the S&P 500?

No, Korro Bio is not included in the S&P 500 index

Is Korro Bio in the NASDAQ 100?

No, Korro Bio is not included in the NASDAQ 100 index

Is Korro Bio in the Dow Jones?

No, Korro Bio is not included in the Dow Jones index

When was Korro Bio the previous earnings report?

No data

When does Korro Bio earnings report?

The next expected earnings date for Korro Bio is 29 November 2024